NiKang Therapeutics, Inc.

NiKang Therapeutics, Inc. is a biotechnology company focused on developing innovative small molecule drugs for challenging oncology targets, aimed at addressing unmet medical needs in cancer treatment. Founded in 2017, NiKang Therapeutics, Inc. is headquartered in Wilmington, US, and specializes in the development of small molecule drugs targeting oncology challenges.

The company has successfully completed 3 deals to date, with the most recent deal occurring on May 19, 2021. Zhenhai Gao, one of the founders, serves as the current CEO. The firm raised USD 200 mn in a Series C funding round, bringing the total amount raised to USD 200 mn and the company valuation to USD 449. 613 mn.

NiKang Therapeutics specializes in developing innovative small molecule drugs for oncology treatment. Its core product candidates include NKT2173, NKT2152, and NKT3964, targeting SHP2, HIF2α, and CDK2, respectively. These therapies are aimed at healthcare providers and oncologists, primarily marketed in the United States and select international markets. NiKang Therapeutics generates revenue through strategic partnerships and collaborations with major pharmaceutical companies, as well as clinical development agreements for its drug candidates.

The company's business model is predominantly B2B, allowing for shared resources and market access. Revenue is derived from milestone payments associated with clinical trial advancements and potential royalties from successful product sales. Following the Series C funding of USD 200 mn raised on May 19, 2021, NiKang Therapeutics plans to utilize the funds to advance its lead drug candidates into clinical trials, expand its drug development pipeline, and support internal drug discovery programs. The company aims to explore new markets to enhance its reach, with a focus on geographic regions that are underserved in terms of advanced cancer therapies.